Ding-Ming Wan
Overview
Explore the profile of Ding-Ming Wan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Chen Y, Yuan H, Xu Y, Huang X, Gao S, et al.
Bone Marrow Transplant
. 2024 Nov;
60(3):310-318.
PMID: 39587323
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy and the only curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT is not appropriate for all...
2.
Jin Y, Zhao P, Zhang Y, Ye Y, Zhou F, Wan D, et al.
Ann Hematol
. 2024 Jul;
103(10):4261-4270.
PMID: 38990296
Membranous nephropathy (MN) is a rare complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT). MN patients may develop nephrotic syndrome or even kidney failure, which greatly affects...
3.
Zhou J, Wang S, Yuan H, Xu Y, Huang X, Gao S, et al.
Am J Hematol
. 2023 Jun;
98(9):1394-1406.
PMID: 37366294
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curable treatment. The outcomes after transplant are influenced by...
4.
Wu K, Guan L, Zhang J, Zhang R, Bian Z, Wang C, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2023 Jun;
31(3):866-870.
PMID: 37356953
Objective: To investigate the risk factors of oral ulcers and bloodstream infection in patients with hematopoietic stem cell transplantation. Methods: The clinical data of 401 hematopoietic stem cell transplant patients...
5.
Fan Y, Wang S, Liu Y, Wang C, Li Y, Wang W, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2022 Feb;
30(1):166-169.
PMID: 35123621
Objective: To analyze the characteristics of gene mutation and overexpression in newly diagnosed multiple myeloma (NDMM) patients. Methods: Bone marrow cells from 208 NDMM patients were collected and analyzed. The...
6.
Mo X, Hong S, Zhao Y, Jiang E, Chen J, Xu Y, et al.
Am J Hematol
. 2022 Jan;
97(4):458-469.
PMID: 35064928
Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We investigated the efficacy, safety, prognostic factors, and...
7.
Wang M, Zhang J, Wan D, Guo R, Cheng Y, Jiang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2021 Oct;
29(5):1645-1648.
PMID: 34627454
Objective: To analyze the clinical characteristics of patients with POEMS syndrome and explore its effective treatment strategies. Methods: The clinical data of 75 patients with POEMS syndrome treated in The...
8.
Tang P, Zheng C, Dong Z, Xie M, Xie X, Sun H, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2021 Oct;
29(5):1606-1609.
PMID: 34627448
Objective: To investigate the expression and clinical significance of serum protein ROCK2 in patients with chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The patients were...
9.
Liu J, Jiang Z, Xie X, Wan D, Cao W, Wang M, et al.
Front Oncol
. 2021 Sep;
11:710545.
PMID: 34485147
Background: Post-transplant relapse remains a principal leading cause of failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with adult acute lymphoblastic leukemia (ALL). The aim of this study...
10.
Xu L, Lu P, Wu D, Sun Z, Liu Q, Han M, et al.
Bone Marrow Transplant
. 2021 Aug;
56(12):2940-2947.
PMID: 34433917
Between 2008 and 2019, 58,914 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) throughout China. In this report, we focus on...